Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Zevor-cel Elicits 100% ORR in Heavily Pretreated Relapsed/Refractory Myeloma

September 22nd 2022

The BCMA-directed CAR T-cell therapy zevorcabtagene autoleucel demonstrated a 100% objective response rate in heavily pretreated patients with relapsed/refractory multiple myeloma

Advice for Community Oncologists Treating Patients With R/R MM

September 15th 2022

Drs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.

Sequencing Therapies in Patients With R/R MM

September 15th 2022

Drs Forsberg and Lipe discuss strategies for sequencing therapies in relapsed/refractory multiple myeloma.

Selecting Patients for Treatment With DARA-Kd

September 15th 2022

Peter Forsberg, MD, offers insight into which patients with multiple myeloma are most suitable for treatment with the DARA-Kd regimen.

CANDOR Trial of Daratumumab Plus Carfilzomib and Dexamethasone in R/R MM

September 8th 2022

Brea Lipe, MD, and Peter Forsberg, MD, review the results of the CANDOR trial evaluating DARA-Kd regimen in R/R multiple myeloma.

Patient Profile 2: A 76-Year-Old Female with R/R MM

September 8th 2022

Brea Lipe, MD, and Peter Forsberg, MD, present the profile of a woman with relapsed/refractory multiple myeloma and share their opinions of the treatment regimen.

Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma

September 6th 2022

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Daratumumab Compliance Rates in Multiple Myeloma Maintained in Real-World Analysis

September 2nd 2022

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Treatment of Patients With MM and High-Risk Cytogenetics

September 1st 2022

Dr Brea Lipe explains at what stages she orders genetic testing in patients with relapsed/refractory multiple myeloma and how she approaches the treatment of patients with high-risk cytogenetics.

Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

September 1st 2022

Oncologists debate which patient populations most benefit from isatuximab plus carfilzomib and dexamethasone.

Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma

September 1st 2022

Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.

Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups

September 1st 2022

Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.

Benefit of Daratumumab Plus RVd Is Maintained Without Additional Toxicities Among Black Patients With NDMM

August 31st 2022

A subgroup analysis of the phase 2 GRIFFIN trial confirmed that Black patients with newly diagnosed multiple myeloma elicited a benefit from treatment with daratumumab added to lenalidomide, bortezomib, and dexamethasone without additional toxicities.

Subcutaneous Isatuximab Elicits Comparable Efficacy, Safety to IV Formulation in Relapsed/Refractory Myeloma

August 31st 2022

Subcutaneous administration of isatuximab through a syringe pump or on-body delivery system demonstrated similar efficacy and safety compared with intravenous isatuximab when combined with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Plinabulin Combo Shows Potential Reduction in Neutropenia Burden in Patients With Myeloma Who Underwent AHCT

August 29th 2022

The combination of plinabulin and pegfilgrastim was well tolerated patients with multiple myeloma who have undergone autologous hematopoietic stem cell transplantation and who have received a high dose of melphalan.

Cilta-cel Induces Favorable MRD Negativity Rates in Heavily Pretreated Myeloma After Prior BCMA-Directed Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines of Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Biallelic Deletion of TNFRSF17 Associated With Resistance to BCMA-Targeting Therapies In Myeloma

August 28th 2022

Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.

Daratumumab Plus RVd Improves Clinical Outcomes in Transplant-Eligible, Newly Diagnosed Multiple Myeloma

August 28th 2022

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.

Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma

August 28th 2022

High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.